TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,255,544 | -49.8% | 252,298 | -13.7% | 0.01% | -46.2% |
Q2 2023 | $4,490,988 | -1.1% | 292,382 | +44.7% | 0.03% | -10.3% |
Q1 2023 | $4,542,913 | +112.8% | 201,997 | +98.9% | 0.03% | +107.1% |
Q4 2022 | $2,135,218 | – | 101,532 | +534278.9% | 0.01% | – |
Q2 2021 | $0 | -100.0% | 19 | -96.6% | 0.00% | – |
Q1 2021 | $14,000 | -98.9% | 560 | -98.8% | 0.00% | -100.0% |
Q4 2020 | $1,231,000 | – | 45,169 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |